Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

Miltenyi Biotec Acquires Gene Therapy Assets from Lentigen Corporation

publication date: Sep 8, 2014
 | 
author/source: Miltenyi Biotec

/MIL 001

Addition of lentiviral gene delivery capabilities complements strategic partnering portfolio. 

Miltenyi Biotec announced today that it has acquired the lentiviral vector manufacturing business and related assets from US company Lentigen Corporation, a global leader in lentiviral technology for cell and gene therapy applications.

The acquisition further strengthens Miltenyi Biotec’s portfolio in cell and gene therapy. Assets obtained in the transaction include a broad range of intellectual property, process technologies, and cGMP-qualified manufacturing facilities. The Lentigen team will join Miltenyi Biotec, and operate through its newly formed, wholly owned US subsidiary Lentigen Technology, Inc. based in Gaithersburg, MD.

Miltenyi Biotec will leverage the combined capabilities by offering customized system and application design in strategic partnerships with clinical investigators and companies to develop and commercialize cell and gene therapies.

“It is our goal at Miltenyi Biotec to become the major supplier of lentiviral vectors for cell and gene therapies, both for clinical research and at commercial scale,” said Stefan Miltenyi, Chief Executive Officer of Miltenyi Biotec. “With the acquisition of the Lentigen assets, we have strengthened our comprehensive portfolio that will enable our current and future partners to proceed in cell therapies efficiently from preclinical testing through human studies to automated manufacturing for widespread commercial therapeutic use, all with a single strategic partner.”

Lentiviral technology provides the most efficient method for delivering genetic material into cells to modulate their function, as demonstrated by recent clinical trials in genetic diseases and oncology indications utilizing lentivirus-modified chimeric antigen receptor (CAR) T cells.

Concurrent with the transaction, the sellers, now operating as Opus Bio, Inc., have been granted certain rights to deploy lentiviral technology in some therapeutic indications, for which Lentigen Technology, Inc. shall be the preferred manufacturing supplier.


more about miltenyi biotec




 

News Channels

 

 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 

 

 

 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events